ArticleAging2019
Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma - a retrospective study using TCGA database.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 193 citations in OpenAlex.
- Prognostic role and mutational characteristics of N6-methyladenosine-related genes in lung adenocarcinoma.Oncology letters · 2025Article
- Identification of IGF2BP3 and CENPA as key regulators of immunophenotypes in renal clear cell carcinoma.Frontiers in genetics · 2025Article
- Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival.BMC cancer · 2024Article
- Decoding the molecular symphony: interactions between the mNAR cancer · 2024Review
- Comprehensive analysis ofTranslational andrology and urology · 2024Article
- RNA NNature reviews. Urology · 2024Review
- Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis.The Journal of clinical investigation · 2024Article
- Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects.Frontiers in oncology · 2024Review
- Interaction of the intestinal cytokines-JAKs-STAT3 and 5 axes with RNA N6-methyladenosine to promote chronic inflammation-induced colorectal cancer.Frontiers in oncology · 2024Review
- The Potential Impact of HNRNPA2B1 on Human Cancers Prognosis and Immune Microenvironment.Journal of immunology research · 2024Article
- N6-methyladenosine methylation in kidney injury.Clinical epigenetics · 2023Review
- An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.BMC bioinformatics · 2023Article
- Article
- Emerging Regulatory Mechanisms of NPhenomics (Cham, Switzerland) · 2023Review
- Research Progress of mBioMed research international · 2023Review
- Analysis of mScientific reports · 2022Article
- A Risk Signature Consisting of Eight mCellular and molecular neurobiology · 2022Article
- Review
- Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte-associated genes.Cancer medicine · 2022Article
- Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer.Journal of translational medicine · 2022Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
m6A is the most common form of mRNA modification. However, little is known about its role in clear cell renal cell carcinoma (ccRCC). This study aims to identify gene signatures and prognostic values of m6A regulators in ccRCC. In this study, a total of 528 ccRCC patients from TCGA database with sequencing and CNV data were included. Survival analysis was performed using log-rank tests and Cox regression model. The association between alteration of m6A regulators and clinicopathological characteristics was examined using chi-square test. The results showed that alteration of m6A regulators was associated with pathologic stage. Patients with any CNVs of the regulatory genes had worse OS and DFS than those with diploid genes. Moreover, deletion of m6A "writer" genes was an independent risk factor for OS, and copy number gain of "eraser" genes could magnify the effect in a synergistic way. Additionally, low expression of the writer gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.